New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
07:56 EDTPFE, BAC, DTV, JPM, AZN, T, LAZLazard shares rise after AT&T mega-deal struck, WSJ says
Shares of Lazard (LAZ) rose yesterday after AT&T (T), which Lazard was the advisor for, announced its deal to acquire DirecTV (DTV), reported The Wall Street Journal. In contrast, JPMorgan (JPM), Bank of America (BAC) and Guggenheim Partners look set to be disappointed and lose out on potential fees as Pfizer's (PFE) bid for AstraZeneca (AZN) appears destined to fail, the report noted. The Journal added that the total value of agreed-upon U.S. deals is up 87% from last year to $585B year-to-date. Reference Link
News For LAZ;JPM;BAC;T;DTV;PFE;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
June 24, 2015
13:23 EDTPFEPfizer says CDC committee votes to recommend MenB vaccine
Pfizer announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted to recommend that decisions to vaccinate adolescents and young adults 16 through 23 years of age against serogroup B meningococcal disease should be made at the individual level with healthcare providers. It added, "Specifically, the ACIP voted that a serogroup B meningococcal vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16 through 18 years of age." Pfizer's Trumenba is FDA-approved for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. The ACIP recommendation will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and approval, Pfizer said.
11:02 EDTPFEPfizer lung cancer treatment granted FDA orphan drug designation
Subscribe for More Information
09:35 EDTTActive equity options trading on open
Subscribe for More Information
09:07 EDTPFE, AZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
08:57 EDTJPMJPMorgan price target raised to $77 from $70 at Argus
Argus increased its price target on JPMorgan based on the bank's cost cutting efforts and expectations for rising interest rates., along with what Argus sees as moderating concerns over litigation expenses and a good investment banking/trading environment. The firm expects the stock's multiple to increase, and it reiterates a Buy rating.
07:19 EDTJPMJPMorgan names Nachimowski head of chemicals dealmaking in EMEA, Bloomberg says
Subscribe for More Information
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
06:37 EDTJPM, BACDeutsche downgrades Citi, Goldman after share rallies
Deutsche Bank analyst Matt O'Connor recommends using the strong share performance of both Citi (C) and Goldman Sachs (GS) as on opportunity to take profits. The analyst this morning downgraded shares of both investment banks to Hold from Buy. Citi is up 21% from the lows on January 30 while Goldman is up 30% since July 1, 2014, the analyst points out. On Citi, O'Connor sees less near term upside with fixed income trading entering a seasonally weak period and core cost reductions largely over. On Goldman, the analyst sees a lack of catalysts to drive the stock meaningfully higher in the near term. His top picks among U.S. Banks are Bank of America (BAC), JPMorgan (JPM), M&T Bank (MTB) and SunTrust (STI).
June 23, 2015
19:31 EDTTT-Mobile petitions FCC to deny certain AT&T spectrum licenses
Subscribe for More Information
16:00 EDTT, BACOptions Update; June 23, 2015
iPath S&P 500 VIX Short-Term Futures down 46c to 17. Option volume leaders: AAPL FB AAPL T BAC MU BTU WMB AMZN TWTR BBRY
14:17 EDTPFEGlycoMimetics to receive $20M payment from Pfizer
Subscribe for More Information
14:01 EDTPFEPfizer announces enrollment of first patient in RESET study
Subscribe for More Information
10:00 EDTTOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:53 EDTPFEPfizer management to meet with FBN Securities
Meeting to be held in New York on June 25 hosted by FBN Securities.
09:36 EDTBAC, TActive equity options trading on open
Subscribe for More Information
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
07:25 EDTPFEPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
06:25 EDTBACBarclays-Stifel deal marks end of Lehman legacy, Business Insider reports
Subscribe for More Information
05:41 EDTT, DTVAT&T upgraded to Buy from Neutral at UBS
UBS analyst John Hodulik upgraded AT&T (T) to Buy citing an attractive valuation at current share levels. Hodulik expects the phone giant's core domestic wireless business to show "meaningful improvement" in Q2. He also thinks financial benefits from the DirecTV (DTV) acquisition are being underappreciated by the market. Hodulik raised his price target for AT&T shares to $42 from $34. The stock was also upgraded this morning by Barclays analyst Amir Rozwadowski. AT&T shares closed yesterday up 5c to $35.04.
05:35 EDTDTV, TAT&T upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Amir Rozwadowski upgraded AT&T (T) to Overweight saying earnings estimates should move higher following the close of the DirecTV (DTV) acquisition. After visiting AT&T's headquarters, Rozwadowski believes synergies from the deal are "too material to ignore." He raised his price target for AT&T shares to $39 from $34. The stock closed yesterday up 5c to $35.04.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use